Lung cancer trial tests best time for immunotherapy
NCT ID NCT07554846
First seen Apr 29, 2026 · Last updated May 01, 2026 · Updated 1 time
Summary
This phase 3 trial studies the best timing for giving the immunotherapy drug toripalimab to people with stage II-IIIA non-small cell lung cancer that can be removed by surgery. It compares giving the drug before surgery, after surgery, or both before and after. The goal is to see which approach helps prevent the cancer from coming back. The study plans to enroll 759 adults aged 18-75 with specific genetic types of lung cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE STAGE II-IIIA NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.